IDiyas

For the Inventor, By the Inventor

San Diego, CA, United States of America

Andrew John Jennings

USPTO Granted Patents = 14 

 

Average Co-Inventor Count = 5.3

ph-index = 6

Forward Citations = 106(Granted Patents)


Location History:

  • La Jolla, CA (US) (2007 - 2008)
  • San Diego, CA (US) (2010 - 2015)

Company Filing History:

goldMedal7 out of 53 
 
Takeda San Diego, Inc.
 patents
silverMedal6 out of 1,177 
 
Takeda Pharmaceutical Company Limited
 patents
bronzeMedal1 out of 2 
 
Takeda California, Inc.
 patents

Years Active: 2007-2015

Loading Chart...
Loading Chart...
14 patents (USPTO):
1. 9187497 - Substituted pyrido[3,2-e]pyrrolo[1,2-a]pyrazines as inhibitors of poly(ADP-ribose)polymerase (PARP) (2015-11-17),
2. 9139598 - Glucokinase activators (2015-09-22),
3. 8822470 - Substituted pyrido[2,3-b]pyrazines (2014-09-02),
4. 8669249 - Poly (ADP-ribose) polymerase (PARP) inhibitors (2014-03-11),
5. 8563730 - Pyrazole and fused pyrazole glucokinase activators (2013-10-22),
6. 8450323 - Substituted derivatives of pyrido[3,2-e][1,4]thiazino[4,3-a]pyrazine and pyrido[3,2-e][1,4]oxazino[4,3-a]pyrazine (2013-05-28),
7. 8124606 - Substituted 7,8,9,10-tetrahydro-5H-dipyrido[1,2-a:3',2′-e]pyrazin-6(6aH)-ones (2012-02-28),
8. 7928105 - Substituted 6a,7,8,9-tetrahydropyrido[3,2-e]pyrrolo[1,2-a]pyrazin-6(5H)-ones (2011-04-19),
9. 7642275 - Histone deacetylase inhibitors (2010-01-05),
10. 7381825 - Histone deacetylase inhibitors (2008-06-03),
11. 7375228 - Histone deacetylase inhibitors (2008-05-20),
12. 7309594 - Crystallization of protein kinase Bα/AKT1 (2007-12-18),
13. 7235672 - Probe, assay and kits for detecting 11β-hydroxysteroid dehydrogenase and modulators thereof (2007-06-26),
14. 7169801 - Histone deacetylase inhibitors (2007-01-30),

Title: Andrew John Jennings: Innovator in Pharmaceutical Compounds

Introduction

Andrew John Jennings is a notable inventor based in San Diego, CA, with a strong focus on innovative compounds in the pharmaceutical industry. With an impressive portfolio of 14 patents, Jennings has made significant contributions to the field, particularly in the development of compounds that inhibit poly(ADP-ribose) polymerase (PARP) and activate glucokinase.

Latest Patents

Among his latest inventions, Jennings has developed substituted pyrido[3,2-e]pyrrolo[1,2-a]pyrazines as inhibitors of PARP. This patent discloses various compounds useful in treating diseases and disorders related to PARP activity, along with pharmaceutical compositions, kits, and methods for their application. Another notable patent focuses on glucokinase activators. These compounds are especially important for metabolic conditions, and the patent outlines both the structure of these compounds and their potential therapeutic applications.

Career Highlights

Jennings has worked with renowned companies such as Takeda San Diego, Inc. and Takeda Pharmaceutical Company Limited, providing him with valuable industry experience. His innovative work in developing therapeutic compounds reflects his commitment to advancing healthcare through scientific research and innovation.

Collaborations

Throughout his career, Jennings has collaborated with esteemed colleagues like Anthony R. Gangloff and Jeffrey Alan Stafford. These partnerships facilitate a synergistic environment that fosters breakthroughs in pharmaceutical research and development.

Conclusion

Andrew John Jennings exemplifies the spirit of innovation in the pharmaceutical industry through his extensive patent portfolio and impactful collaborations. His work not only contributes to scientific knowledge but also holds the potential to improve health outcomes for patients around the world.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…